Vaishali Sanchorawala @vsanchorawala Twitter profile

Last Seen Profiles

@harecrypta

@stw_pdg

@swetashandilya

@Pass_tryout

@stw_pdg

@OddDiligence

@fripoh

@ankoogg

@stw_pdg

@trevasou

@heavenlyhaoz

@jandakembangstw

@DestiDarko

@lusidea52

@pedrohgrande

@Whotfismick

@stw46

@TJRossSF

@DOTZLeSeul

@Bhbekas2

@_alec_17

@livingforag

@Opesanec

@stw_pdg

@itspawul

@NIONX7_

@avenueemoon

@nicorobinloml

@fc_seibudai

@Vejeetah_TFT

@FocusBeatz

@batfiend

@XonitronTV

@S_Stantcheva

@27Ivan_

@pramodsharma29

Vaishali Sanchorawala

@vsanchorawala

1 month

I am deeply moved to announce that my review article on AL amyloidosis is published in the @NEJM on June 27. This date marks the death anniversary of my mentor, Dr. David Seldin, whose guidance was instrumental in my journey. @BU_Amyloidosis

Systemic Light Chain Amyloidosis | NEJM

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...

www.nejm.org

14

46

212

Vaishali Sanchorawala

@vsanchorawala

1 month

I’m excited to share that my latest review article on AL amyloidosis is now published in the New England Journal of Medicine! @BU_Amyloidosis @BUMedicine @The_BMC Systemic Light Chain Amyloidosis | New England Journal of Medicine

Systemic Light Chain Amyloidosis | NEJM

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...

www.nejm.org

25

51

207

Vaishali Sanchorawala

@vsanchorawala

4 years

Historic achievement as Daratumumab is the first drug to be approved by the FDA for the treatment of AL amyloidosis. Outstanding, exciting, fantastic, empowering news for the patients! @JanssenUS @brendanweiss @MyelomaRnD @BU_Amyloidosis @US_FDA

8

39

173

Vaishali Sanchorawala

@vsanchorawala

2 years

PROUD with tears of joy for Presidential award and the best poster awards @a_staron @BU_Amyloidosis

12

11

114

Vaishali Sanchorawala

@vsanchorawala

4 years

I am sincerely humbled and honored to be elected to the board of ISA. Thank you!

BU Amyloidosis Center

@BU_Amyloidosis

4 years

Our director, Dr. Vaishali Sanchorawala, was elected as secretary of the International Society of Amyloidosis. Her term on the board will be for 2 years. Congratulations @vsanchorawala

9

1

41

19

0

97

Vaishali Sanchorawala

@vsanchorawala

28 days

Thrilled to share my latest review article on AL amyloidosis, now published in @NEJM Reflection of invaluable support of my colleagues and mentors. @BU_Amyloidosis

Systemic Light Chain Amyloidosis | NEJM

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...

www.nejm.org

3

13

95

Vaishali Sanchorawala

@vsanchorawala

3 years

How exciting! This trial results led to FDA approval of daratumumab for AL amyloidosis. @BU_Amyloidosis

3

17

87

Vaishali Sanchorawala

@vsanchorawala

1 year

False positive referrals to @BU_Amyloidosis increased from 4% in 2010 to 13% 2021, most frequent source misinterpretation of PYP scan in recent years. Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre

10

23

80

Vaishali Sanchorawala

@vsanchorawala

1 year

Updated conceptual model of AL amyloidosis: A conceptual model of disease - impacts of disease & treatment & relationships among impacts. This model provides symptoms associated with AL by organ involvement, treatment impacts and the effects on patient well-being.

4

29

76

Vaishali Sanchorawala

@vsanchorawala

2 years

Goodbye to doxycyline in AL amyloidosis! @BU_Amyloidosis 1) Reducing fibril formation in a mouse model 2) randomized trial - no effect on PFS when combined with CyBorD 3) no OS advantage when given post SCT

0

25

77

Vaishali Sanchorawala

@vsanchorawala

8 months

Amylite! Incredible news! A groundbreaking diagnostic test for AL amyloidosis has emerged, ushering in a new era of precision and early detection. This holds immense promise for improved patient outcomes and a deeper understanding of this complex condition. #amyloidosis #ASH23

3

16

76

Vaishali Sanchorawala

@vsanchorawala

1 month

5

67

Vaishali Sanchorawala

@vsanchorawala

1 year

Just published! 142 patients with stage IIIb AL amyloidosis remains a heterogenous group but median OS 9 mos. @BU_Amyloidosis @joshgustine Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis

2

18

63

Vaishali Sanchorawala

@vsanchorawala

2 years

Among 1621 patients with AL amyloidosis, we identified 44 probands (2·7%) with 52 relatives affected. The most common disorders in family members were multiple myeloma (48%) and AL amyloidosis (18%). @BU_Amyloidosis @a_staron @karinapverma

Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with...

With limited existing data on hereditary factors in light chain (AL) amyloidosis, we conducted a study of patients with plasma cell dyscrasias or lymphoproliferative disorders in their family...

pubmed.ncbi.nlm.nih.gov

5

14

62

Vaishali Sanchorawala

@vsanchorawala

4 years

@NoopurRajeMD My husband was 103-104F straight for 11 days #COVID19Pandemic

7

16

57

Vaishali Sanchorawala

@vsanchorawala

3 years

Congratulations to Dr Omar Siddiqi @omarsiddiqi of @BU_Amyloidosis Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (AT…

Diflunisal treatment is associated with improved survival for patients with early stage wild-type...

Diflunisal administration in ATTRwt-CM was associated with improved survival and overall stability in clinical and echocardiographic markers of disease with decrement renal function.

pubmed.ncbi.nlm.nih.gov

3

13

59

Vaishali Sanchorawala

@vsanchorawala

1 month

Key points: · AL amyloidosis is a plasma cell disorder, misfolded light chains depositing as fibrils in organs. · Signs & symptoms vary. · Novel treatments offer a better outlook. Systemic Light Chain Amyloidosis | New England Journal of Medicine

Systemic Light Chain Amyloidosis | NEJM

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...

www.nejm.org

5

10

61

Vaishali Sanchorawala

@vsanchorawala

3 years

Our hearty congratulations to Dr Andrea Havasi for her promotion to Associate Professor of Medicine @BUMedicine @bu_bmc_renal @BU_Amyloidosis Richly deserved. You rock, Andrea! @ahavasi1

3

58

Vaishali Sanchorawala

@vsanchorawala

3 years

This is wishing you and your family a very Happy Diwali! May the Festival of Lights lighten your life with happiness, peace and prosperity.

2

1

56

Vaishali Sanchorawala

@vsanchorawala

2 years

Exciting meeting #ISA_2022 . The future of diagnostics and therapeutics of Amyloidosis is bright with engagement of all stakeholders. Congratulations to Dr Schonland and @UHegenbart for organizing a very stimulating flawless meeting @BU_Amyloidosis

1

7

54

Vaishali Sanchorawala

@vsanchorawala

5 months

Instilling hope for patients with relapsed AL amyloidosis: Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

1

28

55

Vaishali Sanchorawala

@vsanchorawala

15 days

Deeply grateful to lead and participate in the clinical trials for AL amyloidosis. Each step forward in this research represents a beacon of hope for patients. #amyloidosis @BU_Amyloidosis @NEJM Systemic Light Chain Amyloidosis

Systemic Light Chain Amyloidosis | NEJM

Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, ...

www.nejm.org

0

5

54

Vaishali Sanchorawala

@vsanchorawala

10 months

Meet the professors: AL amyloidosis #IMS2023 great attendance and a very interactive session @awechalekar @vsanchorawala @BU_Amyloidosis

1

5

53

Vaishali Sanchorawala

@vsanchorawala

2 years

Merlini award at #ISA_2022t to Dr Per Westermark. Richly deserved.

0

3

52

Vaishali Sanchorawala

@vsanchorawala

5 years

Top 5 papers in AL amyloidosis (not for ATTR amyloidosis) for 2019. #myview #ALamyloidosis #inspiredbyMyelomaVR Thread/Countdown below! @BU_Amyloidosis @VincentRK

1

19

50

Vaishali Sanchorawala

@vsanchorawala

3 years

Amyloid Journal impact factor increased to 7.1! Congratulations to the editorial board. @BU_Amyloidosis @ISA_Amyloidosis

0

3

50

Vaishali Sanchorawala

@vsanchorawala

10 months

Stage IIIb AL amyloidosis: better OS in the range of 44-48 months if hem response within 1 mo and cardiac response within 3 mos of treatment. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL...

Key Points. We identified baseline factors predictive of treatment outcomes and prognostic for survival in stage IIIb AL amyloidosis.Early hematologic and

ashpublications.org

1

12

49

Vaishali Sanchorawala

@vsanchorawala

8 months

EMN 22 trial presented by @StatisKastr at #ASH23 of Daratumumab monotherapy in stage IIIb AL Amyloidosis - hem CR/VGPR 50% and cardiac response 27% at 6 months and median OS 10 months! Early diagnosis critical in improving outcomes of #amyloidosis

2

10

50

Vaishali Sanchorawala

@vsanchorawala

2 years

Tracy Joshi @BU_Amyloidosis presents our data on AA amyloidosis. Largest series of 169 patients in the US with AA amyloidosis. So proud of our NP. Congratulations. @TracyAJoshi #ISA_2022

1

9

47

Vaishali Sanchorawala

@vsanchorawala

2 years

Largest collaborative study from 5 countries and 237 patients with AL amyloidosis with renal transplantation and a median f/u of 8.5 years, showing overall and renal graft survival benefit. @BU_Amyloidosis @ahavasi1

0

16

47

Vaishali Sanchorawala

@vsanchorawala

2 months

Incredible groundbreaking diagnostic test, AmyLite assay to quantify kinetically unstable amyloidogenic lambda light chains; homodimer light chain constant domain as a biomarker #ISA24 @BU_Amyloidosis

2

16

46

Vaishali Sanchorawala

@vsanchorawala

3 years

Exciting news of monumental proportion for ATTR Amyloidosis ⁦ @BU_Amyloidosis ⁩ CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis | NEJM

3

13

46

Vaishali Sanchorawala

@vsanchorawala

2 years

Dr Edwards @CamilleVEdwards presenting at the #ISA_2022 from @BU_Amyloidosis . Congratulations for a great well received talk.

0

8

45

Vaishali Sanchorawala

@vsanchorawala

3 years

Dr Andrew Staron @a_staron of @BU_Amyloidosis presenting 40 year longitudinal natural history study of AL amyloidosis in ~2500 patients with improvement in median OS from 1.4yrs to 4.6yrs and changes in causes of death. Congratulations to @a_staron

0

5

45

Vaishali Sanchorawala

@vsanchorawala

2 years

We @The_BMC work hard and play harder! @BUHemeOncFellow @BU_Amyloidosis #ASH22

3

43

Vaishali Sanchorawala

@vsanchorawala

2 years

Are you ready to solve the challenging cases of systemic Amyloidosis? Join us. @paomilani @BU_Amyloidosis #ISA_2022

0

2

45

Vaishali Sanchorawala

@vsanchorawala

3 years

Natural history study of 2337 patients with AL amyloidosis over a 40 year period from @BU_Amyloidosis : Median OS increased form 1.6 to 4.3 yrs and early mortality decreased from 23% to 13% @a_staron @lis589 @TracyAJoshi

0

13

42

Vaishali Sanchorawala

@vsanchorawala

2 years

5:45am to 9:00pm work hours and still need to clear my EPIC inbasket! One more hour on EPIC at home! And on call this weekend! Sure this is the life of every clinician and scientist! #burnout #academia @The_BMC #exhausted

8

1

44

Vaishali Sanchorawala

@vsanchorawala

3 years

We @BU_Amyloidosis remember Dr David Seldin fondly today and everyday. It has been 6 years today since his passing. David Seldin: kind, compassionate, brilliant and humble. Miss you!

5

4

43

Vaishali Sanchorawala

@vsanchorawala

3 years

Mumbai Hematology Group Webinar concluded with an overwhelming response of +500 attendees from 10 countries, learning about "AL amyloidosis: a case based discussion". Honored and delighted to be delivering this webinar. @BU_Amyloidosis #amyloidosis

0

1

44

Vaishali Sanchorawala

@vsanchorawala

5 years

What an amazing day participating and moderating at the #amyloidosisforum at the FDA. Congratulations to @Amyloidosis_ARC for organizing #privatepublicpartenrship event and getting academia, industry, regulatory agency and patients in one room to enhance drug development.

4

43

Vaishali Sanchorawala

@vsanchorawala

3 years

Nephrologist Dr Andrea Havasi @ahavasi1 of @BU_Amyloidosis at #ASH21 presenting management of nephrotic syndrome in AL amyloidosis #amyloidosis

2

3

43

Vaishali Sanchorawala

@vsanchorawala

3 years

Antifibril antibody, Birtamimab (NEOD001), gets @US_FDA Special Protocol Assessment agreement for AFFIRM-AL trial. Exciting times for patients with AL amyloidosis. @ProthenaCorp @BU_Amyloidosis

3

12

41

Vaishali Sanchorawala

@vsanchorawala

8 months

Future is bright for treatment of AL Amyloidosis. @BianchiLab @Amyloid_Planet #ASH2023 #untanglingamyloidosis

2

10

41

Vaishali Sanchorawala

@vsanchorawala

5 years

Congratulations to our neurologist Dr Michelle Kaku for this timely review on peripheral neuropathy in systemic amyloidosis. Neuropathy Associated with Systemic Amyloidosis. - PubMed - NCBI

Neuropathy Associated with Systemic Amyloidosis - PubMed

Peripheral neuropathy occurs in the setting of both hereditary and acquired amyloidosis. The most common form of hereditary amyloidosis is caused by 1 of 140 mutations in the transthyretin (TTR)...

pubmed.ncbi.nlm.nih.gov

1

11

39

Vaishali Sanchorawala

@vsanchorawala

5 months

Today on Rare Disease Day, we @bu_amyloidosis stand with the amyloidosis community to raise awareness and support for those battling this uncommon yet impactful disease. Let's unite in spreading hope, understanding, and advocacy for all affected by amyloidosis. #RareDiseaseDay

1

5

41

Vaishali Sanchorawala

@vsanchorawala

8 months

Significant and exciting news! Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201. With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL amyloidosis to the US. @BU_Amyloidosis

Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing...

LOS ANGELES, Nov. 21, 2023 -- Nexcella, Inc. ("Nexcella", "Company", "We" or "Us"), a clinical-stage biopharmaceutical company engaged in the discovery and

nexcella.com

0

10

40

Vaishali Sanchorawala

@vsanchorawala

3 years

Deeply saddened to hear about the passing of a giant in the field of amyloidosis, Dr Merrill Benson. @BU_Amyloidosis @IndianaUniv

3

12

40

Vaishali Sanchorawala

@vsanchorawala

8 months

Join us #ASH2023 Thanks @Amyloid_Planet for your unwavering commitment to educate everyone about #amyloidosis

3

9

40

Vaishali Sanchorawala

@vsanchorawala

2 years

Bad timing - clinic session with 17 patients, abstract submission deadline for the @ISA_Amyloidosis and eproof for #Britishjournalofhaematology — to get #COVID19 after dodging it for 2+ years! Hope it is a mild case although does not seem like it on Day #2 .

45

1

40

Vaishali Sanchorawala

@vsanchorawala

5 years

2020 to a good start -- one manuscript accepted in Blood @BloodJournal and one in Blood Advances @BloodAdvances !

1

39

Vaishali Sanchorawala

@vsanchorawala

1 year

Pride taking moment for me as a mentor of Joshua Gustine of @BUMedicine matching at MGH for internal medicine residency. @mghmedres @BU_Amyloidosis

2

0

39

Vaishali Sanchorawala

@vsanchorawala

5 years

A new era of amyloidosis: the trends at a major US referral centre

1

12

37

Vaishali Sanchorawala

@vsanchorawala

2 years

Great showing of posters today from @BU_Amyloidosis at #ISA_2022 . Congratulations to @a_staron

0

3

38

Vaishali Sanchorawala

@vsanchorawala

2 years

24 hour urine collection cannot be replaced with a random urine protein to creatinine ratio in AL Amyloidosis @BU_Amyloidosis @lis589 @ahavasi1

1

5

35

Vaishali Sanchorawala

@vsanchorawala

3 years

Daratuumab in AL amyloidosis: NTproBNP > 8500 pg/mL, presence of 1q21 gain and shorter duration of therapy (<12 cycles) are strong negative predictive factors for outcomes with daratumumab in AL amyloidosis. @RSzalat @BU_Amyloidosis

0

10

35

Vaishali Sanchorawala

@vsanchorawala

3 years

First publication of 2022 from @BU_Amyloidosis and honored to participate in the theme issue to honor Prof Merlini Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients’ Needs #mdpihemato via @MDPIOpenAccess

1

7

36

Vaishali Sanchorawala

@vsanchorawala

1 year

Avoid implicit bias in amyloidosis & never skip genetic testing, particularly in minority groups. At @BU_Amyloidosis , 7 self-identified white patients with ATTRV122I and 19 self-identified Black patients with ATTRwt. The presentation of amyloidosis is truly diverse! @a_staron

3

8

36

Vaishali Sanchorawala

@vsanchorawala

4 years

Day 3 of the XVII International Symposium on Amyloidosis to start! Just informed that the total number of attendees for the symposium is 1050! This is the largest in the history of #ISA2020 . Congratulations to Dr Joan Blade and his colleagues @BU_Amyloidosis

2

5

37

Vaishali Sanchorawala

@vsanchorawala

4 years

Appreciate the dedication of all the panelists to be on the @AmyloidosisSupp webinar today! @ahavasi1 @BU_Amyloidosis @vsanchorawala @BrettSperryMD @SLentzsch @Amyloid_Planet @frederickruberg

3

2

35

Vaishali Sanchorawala

@vsanchorawala

2 months

✈️ After a challenging journey filled with delays, cancellations, spending the night at airport and unexpected obstacles, I finally made it to @ISA_Amyloidosis Despite the travel chaos, I'm thrilled to be connecting with brilliant minds and friends. @BU_Amyloidosis #ISA24

1

0

36

Vaishali Sanchorawala

@vsanchorawala

5 years

Best wishes for a peaceful, cheerful, and prosperous New Year! @BU_Amyloidosis

2

1

35

Vaishali Sanchorawala

@vsanchorawala

2 years

Dr Morie Gertz @MorieGertz presenting Birtamimab in Mayo 2012 stage IV AL amyloidosis- posthoc analysis of VITAL trial, which was terminated for futility analysis. #ASH2022 AFFIRM-AL trial ongoing with this antifibril agent in newly diagnosed pts with AL.

1

9

35

Vaishali Sanchorawala

@vsanchorawala

3 years

This is unbelievable: 6 virtual meetings today on 4 different platforms - zoom, webex, google meet, Microsoft teams! Exhausting experience! May be dreams on Skype tonight! @BU_Amyloidosis

2

0

34

Vaishali Sanchorawala

@vsanchorawala

4 years

Organ responses after SCT correspond with overall survival and hematologic response following SCT predicts organ responses. @RSzalat @BU_Amyloidosis Szalat R et al, Organ responses after high dose melphalan and stem cell transplantation in AL amyloidosis Leukemia. 2020;10.1038

0

7

33

Vaishali Sanchorawala

@vsanchorawala

4 years

I have been talking, speaking, walking, dreaming and breathing (hope not) #COVID19Pandemic in the past 4 weeks @Karyopharm @ManishSagar_MD @BenjaminLinas I now just want #amyloidosis ! I cannot believe, I have forgotten to spell #amyloid @BU_Amyloidosis

1

0

34

Vaishali Sanchorawala

@vsanchorawala

9 months

Today, on World Amyloidosis Day, let's raise awareness and support those affected by this rare disease. Together, we can make a difference and offer hope to those living with amyloidosis. #WorldAmyloidosisDay @BU_Amyloidosis

0

9

34

Vaishali Sanchorawala

@vsanchorawala

4 years

Congratulations to @SLentzsch and @vjp8 for one of the largest multicenter report of targeted therapy of Venetoclax in relapsed AL amyloidosis with t(11;14). @BU_Amyloidosis

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis

Blood Cancer Journal - Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis

www.nature.com

1

6

34

Vaishali Sanchorawala

@vsanchorawala

1 month

We are pleased to update you with the latest impact metrics for Amyloid. Journal Impact Factor is 5.2 Please submit your research to Amyloid @ISA_Amyloidosis @tandfonline

2

6

34

Vaishali Sanchorawala

@vsanchorawala

3 years

May you celebrate Thanksgiving with love in your heart, prosperous vision in your mind, and gratitude in your being. Thanksgiving wishes to everyone! @BU_Amyloidosis

0

34

Vaishali Sanchorawala

@vsanchorawala

2 years

Potential pathways for development of imaging as endpoints for drug development in Amyloidosis. Great discussion between academicians, regulators, industry and patient representatives at the #AmyloidosisForum @US_FDA @BU_Amyloidosis @Amyloidosis_ARC

0

5

34

Vaishali Sanchorawala

@vsanchorawala

2 months

President-Elect @myelomaMD @AmyloidMD presents his vision for the next two years. Let's also extend a heartfelt thank you to Dr. Schonland for his outstanding leadership as our past president. @BU_Amyloidosis @ISA_Amyloidosis #ISA24

0

9

34

Vaishali Sanchorawala

@vsanchorawala

1 year

Former Pakistan president Pervez Musharraf dies at age 79 from amyloidosis! Amyloidosis is not as rare as once thought, it is a “zebra without stripes”! @BU_Amyloidosis #amyloidosis #Awareness

1

4

34

Vaishali Sanchorawala

@vsanchorawala

2 years

Profoundly disappointed! We are going backwards in the US.

1

0

34

Vaishali Sanchorawala

@vsanchorawala

1 year

15 cases of AGel amyloidosis, probably the largest experience in the US from @BU_Amyloidosis @lis589 Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and…

Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies...

We report high rates of cranial and peripheral neuropathy, carpal tunnel syndrome and autonomic dysfunction in patients with systemic AGel amyloidosis. The awareness of these features will enable...

pubmed.ncbi.nlm.nih.gov

0

9

32

Vaishali Sanchorawala

@vsanchorawala

11 months

Goodbye to Doxycycline in AL amyloidosis! @BU_Amyloidosis The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up: Amyloid: Vol 30, No 3

Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagno...

Our trial demonstrated that doxycycline combined with CyBorD failed to prolong PFS or cardiac PFS compared with CyBorD alone in cardiac light chain amyloidosis. Registration: URL: https://www.clini...

pubmed.ncbi.nlm.nih.gov

0

12

31

Vaishali Sanchorawala

@vsanchorawala

2 months

Heartfelt thanks to the organizers for a meticulously planned and well coordinated #ISA24 @MarthaGrogan1 @ADispenzieri @MorieGertz @BU_Amyloidosis @ISA_Amyloidosis

0

6

33

Vaishali Sanchorawala

@vsanchorawala

2 years

Summary of brilliant, outstanding and impactful showing by @BU_Amyloidosis at #ISA_2022 in Heidelberg, Germany. Congratulations to the A team! @a_staron @Jmarksloan @CamilleVEdwards @lis589 @TracyAJoshi @wittyremarkhere @joshgustine

0

3

32

Vaishali Sanchorawala

@vsanchorawala

5 years

I just published "Establishment of brain natriuretic peptide -based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis" in "British Journal of Haematology".

2

3

31

Vaishali Sanchorawala

@vsanchorawala

4 years

How I treat systemic AL amyloidosis. @BU_Amyloidosis #ASHMHM20

Vincent Rajkumar

@VincentRK

4 years

Online today: How I Treat Multiple Myeloma. #ASHMHM20 @ASH_hematology @IreneGhobrial @vsanchorawala @ninashah33 @JoshuaRichterMD @MayoClinic @DanaFarber @BUmedical @UCSFHospitals @MountSinaiNYC

1

9

28

0

7

31

Vaishali Sanchorawala

@vsanchorawala

2 years

Satellite Symposium on AL amyloidosis at #ASH2022 . AL amyloidosis not a zebra anymore. High index of clinical suspicion MUST in the right setting of syndromes. @Amyloid_Planet @adsouza_md @ADispenzieri

2

4

31

Vaishali Sanchorawala

@vsanchorawala

6 years

#ISA2018 began! Room full of amyloidologists! @Amyloidosis_BU

1

10

31

Vaishali Sanchorawala

@vsanchorawala

3 years

First FSS at #ASH21 . @BU_Amyloidosis

0

31

Vaishali Sanchorawala

@vsanchorawala

2 months

It is the last day of the ISA meeting! 🎉 We've had an incredible time exchanging ideas. Share your highlights and key takeaways using #ISA24 . Safe travels to everyone heading home! @BU_Amyloidosis @ISA_Amyloidosis

2

3

31

Vaishali Sanchorawala

@vsanchorawala

2 months

Congratulations to the Skinner Award recipients Dr Obici and Dr Westermark! Inaugural Skinner Award presented at @ISA_Amyloidosis #ISA24 @BU_Amyloidosis

1

6

30

Vaishali Sanchorawala

@vsanchorawala

4 years

On this last day if 2020, I want to be grateful to all my colleagues and friends @BU_Amyloidosis for being patient, innovative and collaborative during #COVID19 pandemic. Cheers to a better 2021! #GetVaccinated

2

0

29

Vaishali Sanchorawala

@vsanchorawala

4 years

Hematology/Oncology Clinics of North America Systemic Amyloidosis due to Monoclonal Immunoglobulins Vol 34 (6), Dec 2020 I had the pleasure of writing a chapter on soft tissues involvement in AL amyloidosis @BU_Amyloidosis @Drjhoffmanmiami

0

2

29

Vaishali Sanchorawala

@vsanchorawala

4 years

I PROTECT YOU – YOU PROTECT ME #COVID19Pandemic @BU_Amyloidosis

1

29

Vaishali Sanchorawala

@vsanchorawala

4 years

Happy Diwali 🪔!

2

0

28

Vaishali Sanchorawala

@vsanchorawala

4 years

“Advances in AL Amyloidosis” presented to Mumbai Hematology Group from 6:30 to 8:30am EST. Very humbling experience and a great privilege. Attended by 1000+ trainees and hematologist from all over India. Intelligent questions by the audience. @BU_Amyloidosis

0

1

29

Vaishali Sanchorawala

@vsanchorawala

2 years

Sunshine, flowers, trees blooming, allergic rhinitis, Spring is here! @BU_Amyloidosis

0

29

Vaishali Sanchorawala

@vsanchorawala

2 years

Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, …

In the phase 3 ANDROMEDA trial, patients treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (D-VCd) had significantly higher rates of organ and hematologic response compared...

pubmed.ncbi.nlm.nih.gov

0

6

27

Vaishali Sanchorawala

@vsanchorawala

2 years

Supportive care is crucial in the management of AL amyloidosis @ADispenzieri #ASH22

2

5

27

Vaishali Sanchorawala

@vsanchorawala

3 years

Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis AKI during SCT in AL amyloidosis in 29%, dialysis requirement in 7% and 80% able to discontinue dialysis. @BU_Amyloidosis @ahavasi1 @Ralph__Nader

Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL...

AKI is common in the post-HDM/SCT period and it leads to increased risk for ESKD and death. Our prediction model is an easily deployable tool in clinical settings as part of the discussion with...

pubmed.ncbi.nlm.nih.gov

2

10

28

Vaishali Sanchorawala

@vsanchorawala

3 years

MRD assessment in myeloma! Not ready for prime time to change treatment. Dr Sagar Lonial @SagarLonialMD at #ASH2021 MRD assessment in AL amyloidosis definitely not there yet either! Long way to go! @BU_Amyloidosis @a_staron

0

7

28

Vaishali Sanchorawala

@vsanchorawala

5 years

TTR Amyloidosis meeting for the patients and caregivers in Chicago, organized by @MurielFinkel @AmyloidosisSupp #amyloidosis We @BU_Amyloidosis well represented by @ahavasi1 Dr Rick Ruberg, Dr John Berk and Dr Meena Zareh. Thank you!

0

7

27

Vaishali Sanchorawala

@vsanchorawala

2 years

Blacks underrepresented in clinical trials for myeloma, industry, non profit organizations and academics sponsored trials. We must do better. @Jmarksloan @CharlesMilrod @dhughesPharmD @FrancesBlevins | Home

1

6

27

Vaishali Sanchorawala

@vsanchorawala

1 year

With more diverse profile of patients diagnosed with AL amyloidosis, there is a need to better understand how this may affect various patient groups differently. Shining a spotlight on race & ethnicity in systemic AL amyloidosis @BU_Amyloidosis @a_staron

1

5

27

Vaishali Sanchorawala

@vsanchorawala

1 year

Basis for AFFIRM-AL trial. Enroll patients on this trial of antifibril antibody for AL amyloidosis. @BU_Amyloidosis Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-contr...

Key Points. The VITAL study of birtamimab in all stages of newly diagnosed AL amyloidosis was discontinued early per futility analysis.Birtamimab improved

ashpublications.org

1

13

27

Vaishali Sanchorawala

@vsanchorawala

5 years

Wishes for a Joyous Diwali. May Diwali bring you happiness, fulfillment and prosperity. @BU_Amyloidosis

1

26